HomeAbout UsScienceNewsroomCareersContact
中文 EN
Scroll
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Read More
Newsroom
Press Releases
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
2023/09/21
Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million.
1 / 3
Press Releases
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
2023/07/17
1 / 3
Press Releases
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
2022/04/08
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
1 / 3
Media Coverage
Luhan Yang | With the completion of Pre-B round financing and the first product entering clinical stage, what will be the next step for Qihan Biotech?The Bloomberg 50Luhan Yang, Qihan Biotech: In the name of science, reverence for the greatness of life
Publications
Extensive germline genome engineering in pigsInactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9RNA-guided human genome engineering via Cas9
Read More
Join Our Team
Learn More
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311231
TEL: 0571-83500380
FAX: 0571-83500370